0000912282-26-000811.txt : 20260611 0000912282-26-000811.hdr.sgml : 20260611 20260611120210 ACCESSION NUMBER: 0000912282-26-000811 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260611 DATE AS OF CHANGE: 20260611 EFFECTIVENESS DATE: 20260611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Quince Therapeutics, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-587011 FILM NUMBER: 261082204 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cortexyme, Inc. DATE OF NAME CHANGE: 20160104 D 1 primary_doc.xml X0708 D LIVE 0001662774 Quince Therapeutics, Inc. 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 415-910-5717 CALIFORNIA None Cortexyme, Inc. Corporation true Dirk Thye 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Brigette Roberts 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Charles Ryan 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer Brendan Hannah 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer David Lamond 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Director Christopher Senner 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Director June Bray 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Director Biotechnology Decline to Disclose 06b false 2026-05-18 true true true true true The Issuer issued 2,210,899 shares of common stock, 52,153.299 shares of preferred stock, and warrants to purchase up to 7,410.644 shares of preferred stock in connection with its acquisition of Orphai Technologies, Inc. 0 LifeSci Capital 000168404 None None 1700 Broadway, 40th Floor New York NY NEW YORK 10019 All States 7387671 0 7387671 Offering amount includes aggregate gross proceeds that may be received in the future upon the cash exercise in full of the warrants. false 66 1800000 0 0 false Quince Therapeutics, Inc. /s/ Dirk Thye Dirk Thye Chief Executive Officer 2026-06-11